Lexicon Pharmaceuticals (LXRX) Commencing Dosing for Phase 2a Trial with LX6171 for Treatment of Alzheimer's Disease
Tweet Send to a Friend
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced that dosing has commenced in a Phase 2a clinical trial with LX6171, an oral ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
